Pharmacokinetics and Safety of Endotracheal Lidocaine for Endotracheal Intubation in Critically Ill Children

• Published in: Paediatric drugs Vol. 27; no. 1; pp. 103 - 109
• Main Authors: Anderson, Jordan, Owen, Erin B., Mayes, Shannon, Sullivan, Janice E., McDonald, Mark J.
• Format: Journal Article
• Language: English
• Published: Switzerland 01.01.2025
• Subjects: Adolescent; Anesthetics, Local - administration & dosage; Anesthetics, Local - adverse effects; Anesthetics, Local - blood; Anesthetics, Local - pharmacokinetics; Child; Child, Preschool; Critical Illness - therapy; Female; Humans; Infant; Intensive Care Units, Pediatric; Intubation, Intratracheal - methods; Lidocaine - administration & dosage; Lidocaine - adverse effects; Lidocaine - blood; Lidocaine - pharmacokinetics; Male; Respiration, Artificial
• DOI: 10.1007/s40272-024-00662-6
• ISSN: 1174-5878

Critically ill pediatric patients are endotracheally intubated in pediatric intensive care units for a variety of illnesses and indications. Management of an endotracheal tube (ETT) requires suctioning to remove patient secretions and prevent occlusion, but this practice can be associated with adverse events, such as hemodynamic deterioration or increases in intracranial pressure. Instillation of lidocaine into the ETT before suctioning may be beneficial in preventing these events. The purpose of this phase I, fixed-dose, open-label pharmacokinetic and safety study, conducted in endotracheally intubated and mechanically ventilated infants and children requiring ETT suctioning, was to determine the serum concentrations and safety of lidocaine after ETT administration. A total of 21 infants and children meeting inclusion criteria received a single dose of ETT lidocaine per institutional protocol. Blood samples were obtained pre-dose and at 5, 10, 30, and 120 minutes after administration for serum concentration analysis. Lidocaine dosing was driven by weight and age, with infants and children aged >  38 weeks' estimated gestational age and < 3 years receiving 0.5 mg/kg/dose (maximum: 20 mg/dose) and children aged 3-18 years receiving 1 mg/kg/dose (maximum: 100 mg/dose). No subjects aged < 3 years had detectable serum lidocaine concentrations. Four subjects in the group aged ≥  3 years had detectable serum lidocaine concentrations at 5, 10, and/or 30 minutes, but no serum concentrations were within the toxic range. No adverse effects, such as cough, bronchospasm, seizure activity, or clinically significant depression of cardiac or respiratory function, were noted in any subjects. Pharmacokinetic sampling showed that only 4 of 21 subjects had detectable serum lidocaine concentrations and none were within the toxic range. The safety of ETT administration of lidocaine in endotracheally intubated infants and children requiring ETT suctioning was demonstrated at the doses used in this study. The study was conducted at Norton Children's Hospital. The research team confirmed that this study was not registered with clinicaltrials.gov.